🇺🇸 FDA
Pipeline program

PARACETAMOL , Dapirolizumab pegol, Placebo matching dapirolizumab pegol and without active substance, -, DIPHENHYDRAMINE , -, EPINEPHRINE , -, -

SL0044

Phase 3 small_molecule active

Quick answer

PARACETAMOL , Dapirolizumab pegol, Placebo matching dapirolizumab pegol and without active substance, -, DIPHENHYDRAMINE , -, EPINEPHRINE , -, - for Systemic lupus erythematosus (SLE) is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Systemic lupus erythematosus (SLE)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials